Fig. 1: The design of SAFET platform for CART cell therapy. | Cell Discovery

Fig. 1: The design of SAFET platform for CART cell therapy.

From: CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy

Fig. 1

a Scheme of CRISPR-edited GM-CSF KO CART cells secreting IL6 and IL1 blockers. Patient-derived T cells were engineered with CRISPR/Cas9 RNP for GM-CSF/TCR KO and transduced with lentivector encoding 2nd generation 41BBζ CAR and anti-IL6 scFv and IL1RA for blocking IL6/IL1 signalings. b The construct of lentivector for co-expressing CAR and cytokine blockers.

Back to article page